GlassScriptPhysician profile
Tiffany A Powell
NPI 1255318978
$6,610.29
in general payments reported to CMS, 2019-2025
35 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $931 · 2021: $1,262 · 2022: $1,410 · 2023: $1,069 · 2024: $635 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Education: $74.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.13 |
| Education | $74.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,262.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $817.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Mannkind Corporation | $694.14 | 2019-2023 | Afrezza |
| Abbvie INC. | $606.24 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $417.53 | 2019-2022 | |
| Amgen INC. | $373.73 | 2019-2025 | Repatha, Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $215.09 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $204.90 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $175.59 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $169.94 | 2019-2023 | |
| Abbott Laboratories | $161.37 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $156.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.87 | 2021-2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $113.49 | 2020-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $109.08 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $106.59 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $91.33 | 2021 | |
| Amarin Pharma, INC. | $89.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $88.13 | 2020-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.03 | 2019-2022 | |
| Sanofi Pasteur INC. | $81.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.67 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $73.98 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $43.14 | 2023 | Rexulti |
| Exact Sciences Corporation | $38.65 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $28.95 | 2021 | |
| Almatica Pharma LLC | $28.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.88 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.47 | 2025 | Nuzyra |
| Neurocrine Biosciences, INC. | $20.16 | 2025 | |
| Si-Bone, INC. | $18.16 | 2024 | |
| Vanda Pharmaceuticals INC. | $18.15 | 2021 | |
| Phadia US INC. | $17.63 | 2025 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $14.02 | 2022 | |
| Allergan, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.